GlassScriptPhysician profile
Kylen Whipp
NPI 1104272566
$2,541.13
in general payments reported to CMS, 2019-2025
30 companies · $23.39 in 2025
The $23.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $848 · 2023: $666 · 2024: $587 · 2025: $23.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.12 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Glaxosmithkline, LLC. | $215.08 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $137.26 | 2023-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $136.22 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $128.70 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $99.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $91.13 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.57 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $56.22 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $50.31 | 2021-2023 | |
| Amgen INC. | $49.46 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.28 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.50 | 2023 | Rexulti |
| Philips North America LLC | $33.35 | 2021-2022 | |
| Dexcom, INC. | $32.29 | 2023-2024 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.37 | 2022-2023 | Eliquis |
| Medtronic, INC. | $30.36 | 2024 | Vanta Adaptivestim |
| Inspire Medical Systems, INC. | $28.28 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $26.12 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $25.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.92 | 2023 | Gattex |
| Xeris Pharmaceuticals, INC. | $18.77 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.86 | 2021 | |
| Exact Sciences Corporation | $16.46 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $14.66 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.62 | 2023 | Breztri |
| Amarin Pharma, INC. | $13.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylen Whipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.